Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 1/2 × Acrocephalosyndactylia × derazantinib × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Acrocephalosyndactylia 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Neoplasms 1 Liver Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Biliary Tract Neoplasms 1

Interventions

derazantinib 2 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04604132 2024-04-04

FIDES-03

Basilea Pharmaceutica

Phase 1/2 Terminated

47 enrolled 22 charts

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT04045613 2023-10-13

FIDES-02

Basilea Pharmaceutica

Phase 1/2 Completed

95 enrolled 25 charts

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡